SRR27320674
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 70
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.530
- OXIDATIVE_PHOSPHORYLATION+0.520
- MYC_TARGETS_V2+0.490
- PROTEIN_SECRETION+0.390
- UNFOLDED_PROTEIN_RESPONSE+0.340
- MTORC1_SIGNALING+0.330
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- PEROXISOME+0.290
- FATTY_ACID_METABOLISM+0.270
- PANCREAS_BETA_CELLS+0.220
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- ANGIOGENESIS-0.340
- APICAL_SURFACE-0.330
- NOTCH_SIGNALING-0.310
- MYOGENESIS-0.290
- APICAL_JUNCTION-0.240
- HEDGEHOG_SIGNALING-0.220
- INTERFERON_ALPHA_RESPONSE-0.220
- KRAS_SIGNALING_DN-0.200
- COAGULATION-0.140
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | bf312cd5-e251-4d63-95b5-c379b3ef5ded | — | — | 0.797 |
| 2 | 6f2c5313-1c83-46c7-a15c-5b9526c1763b | — | — | 0.776 |
| 3 | 79a36f11-38bb-42ed-a95a-ae2a9eea0f6a | — | — | 0.774 |
| 4 | dfb9c45f-cb52-4e36-b663-1a9e8c7c0b47 | — | — | 0.772 |
| 5 | 054d5602-4089-4f34-a667-14c8edbb4167 | — | — | 0.766 |
| 6 | TCGA-46-3765-01A-01R-0980-07 | — | cohortSQ2 | 0.765 |
| 7 | TCGA-AO-A0JD-01A-11R-A056-07 | — | C | 0.765 |
| 8 | 8824c0fd-764e-4525-952b-f25efa742772 | — | — | 0.761 |
| 9 | C3L-01862 | — | cohortA4 | 0.760 |
| 10 | 14bc145a-8b15-42d2-bb12-d9a0f75a90f4 | — | — | 0.758 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.530 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.520 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| PEROXISOME | 0.290 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.270 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.220 | Cobimetinib | — uncovered |
| DNA_REPAIR | 0.210 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.210 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.150 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.150 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.130 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.120 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.120 | Inavolisib | — uncovered |
| APOPTOSIS | 0.110 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.090 | Inavolisib | — uncovered |